{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000101","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.451360+00:00","generated_at":"2026-06-01T02:28:42.536056+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arvinas appoints Andrew Saik as CFO, effective June 24, 2024","bullets":["Andrew Saik, former Intercept Pharmaceuticals CFO, named permanent CFO at Arvinas.","Base salary of $525,000; annual bonus target of 45% of base salary.","Granted 94,418 options and 61,409 RSUs, both vesting over four years.","Randy Teel, Ph.D., who served as interim CFO, returns to chief business officer role."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000101","json":"https://secwatch.observer/filing/0001655759-24-000101.json","markdown":"https://secwatch.observer/filing/0001655759-24-000101.md","text":"https://secwatch.observer/filing/0001655759-24-000101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000101/0001655759-24-000101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000101/arvn-20240622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:28:42.536056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}